{"id":686384,"date":"2024-01-31T17:20:02","date_gmt":"2024-01-31T17:20:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=686384"},"modified":"2024-01-31T17:20:02","modified_gmt":"2024-01-31T17:20:02","slug":"nontuberculous-mycobacterial-ntm-infections-market-to-expand-at-a-significant-growth-rate-during-the-forecast-period-202332-estimates-delveinsight-insmed-novoteris-savara-beyond-air","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/nontuberculous-mycobacterial-ntm-infections-market-to-expand-at-a-significant-growth-rate-during-the-forecast-period-202332-estimates-delveinsight-insmed-novoteris-savara-beyond-air_686384.html","title":{"rendered":"Non-tuberculous Mycobacterial (NTM) Infections Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) – Estimates DelveInsight | Insmed, Novoteris, Savara, Beyond Air"},"content":{"rendered":"
\n
\"Non-tuberculous<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Non-tuberculous Mycobacterial (NTM) Infections Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Non-tuberculous Mycobacterial (NTM) Infections and the expected launch of emerging therapies such as Arikayce, SPR720, Thiolanox (Nitric Oxide), NUZYRA (omadacycline), Molgramostim, and others.<\/div>\n

DelveInsight’s “Non-tuberculous Mycobacterial (NTM) Infections Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Non-tuberculous Mycobacterial (NTM) Infections market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Non-tuberculous Mycobacterial (NTM) Infections drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Non-tuberculous Mycobacterial (NTM) Infections treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

Non-tuberculous Mycobacterial (NTM) Infections: An Overview<\/strong><\/p>\n

According to the Centers for Disease Control and Prevention (CDC), NTM is also referred to as atypical mycobacteria, mycobacteria other than tuberculosis (MOTT), or environmental mycobacteria. It is a ubiquitous, aerobic, non-motile, acid-fast bacteria commonly found in soil and water. Inhalation of these bacteria may cause disease in both healthy persons and those with compromised immune systems.<\/p>\n

NTMs can cause infections in a wide variety of body sites, most commonly the lungs and in the following areas: Skin and soft tissue, device-associated infections, Lymph nodes, Blood, or other usually sterile locations in the body. In NTM disorders, the severity of infection and the disease course can vary greatly from one person to another.<\/p>\n

The recurrence rate of NTM infection after antibiotic therapy ranges from 20% to 45%. Patients experiencing relapse\/recurrence after being treated with antibiotics are then considered for treatment with surgical interventions.<\/p>\n

A diagnosis of non-tuberculous mycobacterial disease is based upon the identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation, and a variety of specialized tests. However, the diagnosis can be challenging because the characteristic signs and symptoms are highly variable and nonspecific.<\/p>\n

Non-tuberculous Mycobacterial (NTM) Infections Market Key Facts<\/strong><\/p>\n